Drugs / Pegylated Recombinant Human Granulocyte Stimulating Factor
Pegylated Recombinant Human Granulocyte Stimulating Factor
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy2 trials | ||||||
| Phase 2 | NCT06741722 Background | Oct 2024 → Oct 2026 expected | acute myeloid leukemia | Beijing 302 Hospital | Recruiting | No outcome recorded |
| Phase 2 | NCT04541277 Background | Sep 2020 → Aug 2021 | acute myeloid leukemia | Chinese PLA General Hospital | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Pegylated Recombinant Human Granulocyte Stimulating Factor | “Pegylated Recombinant Human Granulocyte Stimulating Factor Injection: 100 μg/kg, subcutaneous injection, on Day 0” NCT06741722 ↗1“Pegylated recombinant human granulocyte stimulating factor injection Liquid, 100 μg/kg, SC, on day 0.” NCT04541277 ↗ |
| Modality | Protein / enzyme biologic | “Pegylated Recombinant Human Granulocyte Stimulating Factor Injection” NCT06741722 ↗ |
| Route | Subcutaneous | “Pegylated recombinant human granulocyte stimulating factor injection Liquid, 100 μg/kg, SC” NCT04541277 ↗ |